1. Home
  2. EVLV vs SNDX Comparison

EVLV vs SNDX Comparison

Compare EVLV & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVLV
  • SNDX
  • Stock Information
  • Founded
  • EVLV 2013
  • SNDX 2005
  • Country
  • EVLV United States
  • SNDX United States
  • Employees
  • EVLV N/A
  • SNDX N/A
  • Industry
  • EVLV Computer peripheral equipment
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVLV Technology
  • SNDX Health Care
  • Exchange
  • EVLV Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • EVLV 1.4B
  • SNDX 1.3B
  • IPO Year
  • EVLV N/A
  • SNDX 2016
  • Fundamental
  • Price
  • EVLV $8.28
  • SNDX $13.82
  • Analyst Decision
  • EVLV Strong Buy
  • SNDX Strong Buy
  • Analyst Count
  • EVLV 4
  • SNDX 11
  • Target Price
  • EVLV $8.88
  • SNDX $38.55
  • AVG Volume (30 Days)
  • EVLV 2.5M
  • SNDX 3.1M
  • Earning Date
  • EVLV 11-13-2025
  • SNDX 10-31-2025
  • Dividend Yield
  • EVLV N/A
  • SNDX N/A
  • EPS Growth
  • EVLV N/A
  • SNDX N/A
  • EPS
  • EVLV N/A
  • SNDX N/A
  • Revenue
  • EVLV $121,011,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • EVLV $31.07
  • SNDX $641.22
  • Revenue Next Year
  • EVLV $17.67
  • SNDX $110.64
  • P/E Ratio
  • EVLV N/A
  • SNDX N/A
  • Revenue Growth
  • EVLV 36.64
  • SNDX 2126.66
  • 52 Week Low
  • EVLV $2.04
  • SNDX $8.58
  • 52 Week High
  • EVLV $8.91
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • EVLV 56.91
  • SNDX 36.78
  • Support Level
  • EVLV $7.61
  • SNDX $14.08
  • Resistance Level
  • EVLV $8.31
  • SNDX $15.93
  • Average True Range (ATR)
  • EVLV 0.43
  • SNDX 1.03
  • MACD
  • EVLV 0.00
  • SNDX -0.18
  • Stochastic Oscillator
  • EVLV 64.51
  • SNDX 22.55

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: